105 related articles for article (PubMed ID: 6128635)
1. Acetylator phenotype in bladder cancer.
Miller ME
Lancet; 1982 Dec; 2(8311):1348. PubMed ID: 6128635
[No Abstract] [Full Text] [Related]
2. Acetylator phenotype in human bladder cancer.
Miller ME; Cosgriff JM
J Urol; 1983 Jul; 130(1):65-6. PubMed ID: 6864917
[TBL] [Abstract][Full Text] [Related]
3. The association of the slow acetylator phenotype with bladder cancer.
Evans DA; Eze LC; Whibley EJ
J Med Genet; 1983 Oct; 20(5):330-3. PubMed ID: 6644762
[TBL] [Abstract][Full Text] [Related]
4. Hepatic acetylator phenotype in bladder cancer patients.
Ladero JM; Kwok CK; Jara C; Fernandez L; Silmi AM; Tapia D; Uson AC
Ann Clin Res; 1985; 17(3):96-9. PubMed ID: 4051447
[TBL] [Abstract][Full Text] [Related]
5. Genetically determined sparteine oxidation and sulfadimidine acetylation polymorphism in patients with non-occupational urinary bladder cancer.
Orzechowska-Juzwenko K; Niewiński P; Pawlik J; Milejski P; Dembowski J; Swiebodzki L; Lorenz J
Mater Med Pol; 1994; 26(4):145-8. PubMed ID: 7666680
[TBL] [Abstract][Full Text] [Related]
6. N-acetylation phenotype in bladder cancer.
Woodhouse KW; Adams PC; Clothier A; Mucklow JC; Rawlins MD
Hum Toxicol; 1982 Oct; 1(4):443-5. PubMed ID: 7173929
[TBL] [Abstract][Full Text] [Related]
7. [The acetylator phenotype in patients with urinary bladder cancer].
Wich H; Franke G; Grimm U; Siegmund W
Z Urol Nephrol; 1989 Nov; 82(11):597-9. PubMed ID: 2618184
[TBL] [Abstract][Full Text] [Related]
8. [Acetylation phenotype in patients with cancer of the bladder. Preliminary report].
Skretowicz J; Polakowski P; Jeromin L; Zasada M; Szymańska J; Krajewska B
Med Pr; 1988; 39(4):241-5. PubMed ID: 3237058
[TBL] [Abstract][Full Text] [Related]
9. Survey of the human acetylator polymorphism in spontaneous disorders.
Evans DA
J Med Genet; 1984 Aug; 21(4):243-53. PubMed ID: 6387123
[TBL] [Abstract][Full Text] [Related]
10. Overrepresentation of the slow acetylator phenotype in painters suffering from urinary bladder cancer.
Golka K; Kempkes M; Flieger A; Blaszkewicz M; Bolt HM
Med Lav; 1997; 88(5):425-6. PubMed ID: 9489306
[No Abstract] [Full Text] [Related]
11. Urinary bladder cancer in a girl with a slow-acetylator genotype and treated with sulphasalazine.
Filiadis IF; Georgiou IA; Giannakopoulos X
Br J Urol; 1998 Feb; 81(2):342-3. PubMed ID: 9488096
[No Abstract] [Full Text] [Related]
12. DNA adduct levels in congenic rapid and slow acetylator mouse strains following chronic administration of 4-aminobiphenyl.
Flammang TJ; Couch LH; Levy GN; Weber WW; Wise CK
Carcinogenesis; 1992 Oct; 13(10):1887-91. PubMed ID: 1423849
[TBL] [Abstract][Full Text] [Related]
13. Commentary: Reflections on G. M. Lower and colleagues' 1979 study associating slow acetylator phenotype with urinary bladder cancer: meta-analysis, historical refinements of the hypothesis, and lessons learned.
Rothman N; Garcia-Closas M; Hein DW
Int J Epidemiol; 2007 Feb; 36(1):23-8. PubMed ID: 17510073
[No Abstract] [Full Text] [Related]
14. Role of N-acetyltransferase phenotype in human susceptibility to bladder carcinogenic arylamines.
Wolf H; Lower GM; Bryan GT
Scand J Urol Nephrol; 1980; 14(2):161-5. PubMed ID: 7209420
[TBL] [Abstract][Full Text] [Related]
15. N-acetylation phenotype and genotype and risk of bladder cancer in benzidine-exposed workers.
Hayes RB; Bi W; Rothman N; Broly F; Caporaso N; Feng P; You X; Yin S; Woosley RL; Meyer UA
Carcinogenesis; 1993 Apr; 14(4):675-8. PubMed ID: 8472331
[TBL] [Abstract][Full Text] [Related]
16. Acetylation phenotypes in patients with bladder carcinoma.
Bicho MP; Breitenfeld L; Carvalho AA; Manso CF
Ann Genet; 1988; 31(3):167-71. PubMed ID: 3265609
[TBL] [Abstract][Full Text] [Related]
17. N-acetyltransferase phenotype and risk in urinary bladder cancer: approaches in molecular epidemiology. Preliminary results in Sweden and Denmark.
Lower GM; Nilsson T; Nelson CE; Wolf H; Gamsky TE; Bryan GT
Environ Health Perspect; 1979 Apr; 29():71-9. PubMed ID: 510245
[TBL] [Abstract][Full Text] [Related]
18. N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk.
Hein DW
Oncogene; 2006 Mar; 25(11):1649-58. PubMed ID: 16550165
[TBL] [Abstract][Full Text] [Related]
19. The biochemical indices of genetic susceptibility to cancer. Acetylation phenotype and bladder cancer.
Hanke J; Krajewska B
Pol J Occup Med; 1988; 1(4):306-11. PubMed ID: 2979565
[No Abstract] [Full Text] [Related]
20. N-acetyltransferase 2 phenotype but not NAT1*10 genotype affects aminobiphenyl-hemoglobin adduct levels.
Probst-Hensch NM; Bell DA; Watson MA; Skipper PL; Tannenbaum SR; Chan KK; Ross RK; Yu MC
Cancer Epidemiol Biomarkers Prev; 2000 Jun; 9(6):619-23. PubMed ID: 10868698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
